KalVista Pharmaceuticals, Inc. is a pharmaceutical company delivering medical solutions globally. Its core operation lies in developing novel therapies for the treatment of hereditary angioedema and diabetic macular edema.
Operating within the biotechnology and medical research sector, KalVista Pharmaceuticals sets itself apart through its approach to drug development and introduction of new therapies into the market. Its influence expands through various collaborations and partnerships across the healthcare landscape.
Stay up to date on the share price of KALV by adding it to your eToro watchlist.